Kristen Hege, Bristol Myers Squibb SVP, early clinical development, oncology/hematology and cell therapy (Illustration: Assistant Editor Kathy Wong for Endpoints News)

Q&A: Bris­tol My­er­s' Kris­ten Hege on cell ther­a­py, can­cer pa­tients and men­tor­ing the next gen­er­a­tion

Kris­ten Hege leads Bris­tol My­ers Squibb’s ear­ly on­col­o­gy dis­cov­ery pro­gram car­ry­ing on from the same work at Cel­gene, which was ac­quired by BMS in 2019. She’s known for her ear­ly work in CAR-T, hav­ing pi­o­neered the first CAR-T cell tri­al for sol­id tu­mors more than 25 years ago.

How­ev­er, the em­i­nent physi­cian-sci­en­tist is more than just a drug de­vel­op­er mas­ter­mind. She’s al­so a prac­tic­ing physi­cian, moth­er to two young women, an avid back­pack­er and in­ter­sect­ing all those in­ter­ests — a cham­pi­on of young women and peo­ple of col­or in STEM and life sci­ences.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.